Clinical Trial Update: Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating the PET imaging agent Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in invasive breast cancer has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) (18F-FLT)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IIB Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-01-20